List of Excipients in Branded Drug VASOPRESSIN IN 0.9% SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin in 0.9% sodium chloride	0338-9640	SODIUM CHLORIDE
Baxter Healthcare Corporation	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin in 0.9% sodium chloride	0338-9640	SODIUM LACTATE
Baxter Healthcare Corporation	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin in 0.9% sodium chloride	0338-9640	WATER
Long Grove Pharmaceuticals LLC	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin	81298-8552	ASPARTIC ACID
Long Grove Pharmaceuticals LLC	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin	81298-8552	BORIC ACID
Long Grove Pharmaceuticals LLC	VASOPRESSIN IN 0.9% SODIUM CHLORIDE	vasopressin	81298-8552	CHLOROBUTANOL

Vasopressin in 0.9% Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 29, 2026

Vasopressin in 0.9% sodium chloride is a ready-to-use intravenous vasopressin product designed to eliminate bedside dilution of concentrated vasopressin injection. Its commercial value is driven less by active-ingredient exclusivity than by formulation stability, container-closure performance, medication-error reduction, hospital workflow, supply reliability, and manufacturing scale.

The formulation is technically simple: vasopressin, sodium chloride, and water for injection. The development challenge is not excipient complexity. It is maintaining peptide potency and purity throughout sterilization, filling, storage, transportation, and administration while preserving a clinically familiar isotonic presentation.

What is vasopressin in 0.9% sodium chloride?

Vasopressin in 0.9% sodium chloride is a premixed intravenous solution containing synthetic vasopressin in normal saline. The product is used primarily in intensive-care and emergency settings for vasodilatory shock, including septic shock and post-cardiotomy vasoplegia, under labeling specific to the approved product.

Premixing provides several operational benefits:

• Eliminates manual dilution from a concentrated vial.
• Reduces calculation and preparation errors.
• Standardizes concentration across hospital departments.
• Reduces pharmacy compounding labor.
• Supports rapid administration during hemodynamic emergencies.
• Creates a differentiated commercial product even when vasopressin itself is generic.

Typical ready-to-use presentations include concentrations such as 0.2 units/mL and 0.4 units/mL, supplied in 100 mL flexible bags. Exact strengths, storage conditions, and approved indications depend on the product label.

What are the active and inactive ingredients?

The core formulation uses:

Component	Function
Vasopressin	Active peptide vasopressor
Sodium chloride	Isotonicity agent and vehicle component
Water for injection	Solvent

The absence of preservatives is commercially relevant. Vasopressin is administered intravenously in acute-care environments, where a single-use, preservative-free presentation is generally preferred. The product does not require a complex excipient platform such as a surfactant, co-solvent, lipid system, or lyophilized cake former.

The formulation must maintain an appropriate pH and osmolality while minimizing peptide degradation, adsorption to processing equipment, and interaction with the container system. Product-specific labeling controls the applicable pH range, storage temperature, beyond-use conditions after opening, and protection from light.

How does the excipient strategy affect vasopressin stability?

The principal excipient strategy is a minimal, isotonic aqueous system. This approach has regulatory and commercial advantages, but it places greater pressure on the manufacturing process and container-closure system.

Peptide degradation risks

Vasopressin is a cyclic nonapeptide. Potential degradation pathways include:

• Oxidation of susceptible amino-acid residues.
• Deamidation.
• Hydrolysis.
• Aggregation or oligomer formation.
• Adsorption to glass, polymer, filters, tubing, or other contact surfaces.
• Potency loss during terminal sterilization or extended storage.

A minimal formulation reduces the number of variables but does not eliminate stability risks. The sponsor must establish that the selected saline concentration, pH, container material, sterilization process, and headspace conditions preserve potency and purity over the proposed shelf life.

Why sodium chloride is commercially useful

0.9% sodium chloride is familiar to hospitals, compatible with standard intravenous practice, and easy to source globally. Its use provides:

• Immediate clinical recognition.
• Straightforward compendial control.
• Broad compatibility with hospital infusion protocols.
• Lower excipient cost than buffered or solubilized systems.
• Reduced regulatory complexity compared with novel excipient combinations.

The commercial tradeoff is limited differentiation. Sodium chloride itself is not a strong proprietary barrier. Product value therefore shifts to concentration design, packaging, stability data, supply performance, and workflow claims.

Should a sponsor add a buffer or stabilizer?

A buffer, antioxidant, surfactant, or chelating agent could improve stability in some development programs, but each addition creates regulatory and commercial costs.

Excipient option	Potential benefit	Principal cost or risk
Phosphate or citrate buffer	pH control	New compatibility, toxicity, and precipitation assessment
Antioxidant	May reduce oxidative degradation	New impurity profile and regulatory justification
Surfactant	May reduce surface adsorption	Parenteral tolerability and extractables concerns
Chelating agent	May control metal-catalyzed degradation	Additional qualification and safety assessment
No added stabilizer	Simple composition and lower regulatory burden	Greater dependence on process and packaging controls

For a mature injectable product, the preferred strategy is generally to retain the simplest formulation that meets potency, purity, sterility, particulate, container-closure, and shelf-life requirements. A new excipient is commercially defensible only if it supports a measurable benefit, such as longer room-temperature stability, reduced adsorption, lower impurity growth, or a materially longer shelf life.

What formulations are protected by vasopressin patents?

The principal patent opportunity is not the basic use of sodium chloride as an excipient. The strongest potential protection would usually attach to a specific combination of:

• Vasopressin concentration.
• pH range.
• Stability profile.
• Container material.
• Oxygen-control strategy.
• Sterilization method.
• Filling process.
• Storage condition.
• Administration-ready format.
• Defined impurity limits over time.

A formulation patent may claim a narrow composition or a result-effective range. A process patent may claim a manufacturing sequence that produces a specified purity or stability profile. A container-closure patent may focus on polymer composition, multilayer construction, oxygen transmission, or adsorption control.

The practical strength of such claims depends on whether the claimed features are visible in a competitor’s product. A composition claim can be easier to enforce than a process claim if the finished product reveals the relevant parameters. A process claim may be commercially important but difficult to detect without discovery.

How strong is the patent estate for vasopressin in normal saline?

The underlying vasopressin molecule is old, and sodium chloride is a conventional parenteral vehicle. This makes broad composition-of-matter protection unlikely. Patent strength is therefore generally lower than for a newly discovered small molecule or a novel biologic formulation.

The most defensible patent positions are likely to involve:

1. A specific ready-to-use concentration.
2. A defined stability profile without refrigeration.
3. A particular flexible-bag or multilayer container.
4. Low-adsorption manufacturing and storage conditions.
5. A process that limits peptide-related impurities.
6. A hospital-use method that reduces dilution or preparation errors.

Trade secrets may be more important than patents for aseptic filling parameters, filtration conditions, headspace management, hold times, and container treatment.

What is the Orange Book status of vasopressin products?

FDA Orange Book treatment depends on the specific approved application and whether the sponsor has listed patents for that application. Concentrated vasopressin injection and premixed vasopressin in sodium chloride may have different application numbers, strengths, dosage forms, and patent listings.

The relevant regulatory questions are:

• Is the product listed as a reference listed drug or a generic equivalent?
• Are patents listed against the product’s specific NDA?
• Do the listed patents cover the premixed presentation?
• Are any patents method-of-use only?
• Has pediatric exclusivity extended a listed patent term?
• Have all listed patents expired, been delisted, or become irrelevant to a proposed ANDA?

FDA’s Orange Book does not establish freedom to operate. It identifies listed patents and approved therapeutic equivalence information. A generic applicant must separately evaluate formulation, manufacturing, packaging, labeling, and method-of-use risks.

For a premixed product, the absence of a broad active-ingredient patent does not eliminate regulatory barriers. The applicant must still demonstrate pharmaceutical equivalence, bioequivalence where applicable, sterility, container-closure integrity, stability, and compliance with injectable-product quality requirements.

When does vasopressin lose exclusivity?

Vasopressin has no meaningful new-molecule exclusivity opportunity because the active ingredient has been used clinically for decades. Market exclusivity for modern products is more likely to arise from:

• Product-specific formulation patents.
• Method-of-use patents.
• Three-year exclusivity for a qualifying new clinical investigation.
• Orphan-drug exclusivity if the product satisfies orphan requirements.
• Pediatric exclusivity.
• Regulatory exclusivity attached to a novel delivery or dosage form.

For a conventional ready-to-use vasopressin saline product, the commercial loss of exclusivity is likely to occur through generic competition, contract-manufacturing entry, hospital purchasing substitution, or institutional adoption of alternative presentations rather than through expiration of a foundational molecule patent.

What generic entry risks exist?

Generic entry risk is material because:

• The active ingredient is established.
• The vehicle is conventional.
• The product is a sterile aqueous injection.
• Hospitals routinely purchase through tenders and group purchasing organizations.
• Buyers can substitute among approved concentrations if clinical protocols permit.
• The product has limited excipient differentiation.

The strongest defense is a combination of reliable supply, validated shelf life, concentration standardization, shortage performance, and procurement contracts. Patent litigation alone is unlikely to sustain a premium for a simple saline-based premix unless the patent claims a narrow, commercially necessary feature.

Are biosimilar risks relevant to vasopressin?

No. Vasopressin is a synthetic peptide drug, not a biologic subject to the biosimilar pathway under section 351 of the Public Health Service Act. Competitive products would generally be evaluated through the drug approval framework, most commonly an ANDA or, where differences require clinical or other supporting data, a 505(b)(2) application.

The relevant competitive threat is generic or follow-on drug entry, not biosimilar substitution.

Which companies are challenging the vasopressin market?

Competition can arise from several groups:

Competitor type	Competitive mechanism
Generic injectable manufacturers	Lower acquisition price for concentrated or premixed products
Branded hospital injectable companies	Ready-to-use packaging and supply contracts
Large contract manufacturers	High-volume sterile manufacturing and tender pricing
Hospital pharmacies	Internal dilution or compounding where permitted
Alternative vasopressors	Norepinephrine, epinephrine, phenylephrine, and angiotensin II may compete clinically
Distribution partners	Availability, allocation, and emergency-stock performance

The principal competitive distinction is not usually molecular innovation. It is the hospital’s total cost of use, including preparation time, pharmacy labor, wastage, medication-error risk, inventory complexity, and availability during shortages.

What commercial opportunities exist for excipient and packaging innovation?

Ready-to-use concentration portfolio

A sponsor can create a product family with standardized concentrations aligned to common ICU protocols. The objective is to reduce bedside calculations and prevent selection errors. Each additional concentration increases manufacturing and inventory complexity, so the portfolio should be limited to concentrations supported by hospital utilization data.

Longer room-temperature stability

Room-temperature stability has direct commercial value. It can:

• Simplify emergency-department and ICU storage.
• Reduce cold-chain dependence.
• Lower pharmacy handling costs.
• Improve disaster and transport readiness.
• Reduce product loss from temperature excursions.

A stability claim must be supported by real-time and accelerated data, impurity characterization, container-closure studies, and shipping validation.

Low-adsorption container systems

Vasopressin may interact with contact surfaces. A low-adsorption polymer, multilayer bag, or treated administration pathway could support a differentiated product if it demonstrates improved delivered dose or reduced potency loss.

Potential proprietary features include:

• Multilayer polyolefin constructions.
• Low-binding tubing.
• Surface treatments.
• Reduced oxygen transmission.
• Defined extractables and leachables controls.
• Optimized fill volume and headspace.

PVC-free and DEHP-free packaging

PVC-free and DEHP-free systems may appeal to hospitals with environmental, occupational, or procurement requirements. The commercial benefit is strongest when the packaging maintains equivalent handling, pump compatibility, container integrity, and shelf life.

Smaller-volume presentations

A smaller bag could reduce waste in lower-dose or short-duration use. The opportunity must be balanced against increased packaging cost and the risk that the product is perceived as a niche presentation.

Dual-source and shortage-resilient supply

Vasopressin has experienced supply pressure in the U.S. market. A sponsor with validated secondary manufacturing, redundant raw-material sources, and high service levels can compete on continuity rather than price alone. Hospitals may pay a modest premium for dependable supply of a critical-care vasopressor.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers are more significant than excipient barriers. Critical controls include:

• Peptide raw-material identity and purity.
• Oxidation control.
• Low-bioburden processing.
• Sterile filtration or validated terminal sterilization.
• Aseptic filling.
• Container-closure integrity.
• Particulate control.
• Adsorption during compounding and filling.
• Hold-time validation.
• Shipping vibration and temperature studies.
• Stability-indicating analytical methods.

The highest-value know-how may reside in the process window that delivers consistent potency and impurity control at commercial scale. Even where patent protection is weak, a manufacturer with reliable sterile capacity and an established hospital distribution network can retain meaningful market share.

How does vasopressin compare with competing vasopressors?

Product	Typical commercial differentiation
Vasopressin in 0.9% sodium chloride	Premixed, non-catecholamine vasopressor; workflow and supply value
Concentrated vasopressin injection	Lower unit cost but requires dilution and preparation
Norepinephrine premix	Broad first-line use in septic shock and strong hospital familiarity
Phenylephrine injection or premix	Alternative vasoconstrictor with different clinical positioning
Epinephrine injection or infusion	Broad emergency and critical-care use
Angiotensin II	Novel mechanism and higher-cost specialty positioning

Vasopressin’s commercial position depends on protocol inclusion and combination use, especially where clinicians use it as an adjunct to norepinephrine. A premixed product can gain share even without clinical superiority if it reduces preparation burden and improves standardized administration.

What litigation and settlement issues should investors monitor?

Relevant disputes may include:

• Paragraph IV challenges to listed patents.
• Patent litigation involving concentrated vasopressin products.
• Claims directed to ready-to-use formulations.
• Container and manufacturing-process disputes.
• ANDA labeling or method-of-use disputes.
• Supply, distribution, or contract-manufacturing litigation.
• Antitrust allegations involving settlements or product withdrawal.

A settlement that permits an authorized generic or delayed entry can materially change price erosion. The commercial impact depends on the number of entrants, the availability of premixed alternatives, and whether hospitals treat the products as interchangeable.

Key Takeaways

• Vasopressin in 0.9% sodium chloride is a formulation and workflow product, not a molecule-exclusivity product.
• The core formulation is intentionally simple: vasopressin, sodium chloride, and water for injection.
• The highest-value technical issues are peptide stability, adsorption, oxygen exposure, container compatibility, sterility, and shelf life.
• Broad patent protection is unlikely for vasopressin in normal saline. Narrow formulation, process, container, and method-of-use claims offer the more realistic patent opportunities.
• The product is subject to generic competition rather than biosimilar competition.
• Commercial differentiation is strongest in ready-to-use concentrations, room-temperature stability, low-adsorption packaging, shortage resilience, and hospital procurement performance.
• Manufacturing know-how and sterile capacity may provide stronger practical barriers than patents.
• Generic entry can produce rapid price pressure unless the branded product has superior supply reliability, packaging, or purchasing-contract coverage.

FAQs

Can sodium chloride itself support a patent for a vasopressin product?

No. Sodium chloride is a conventional parenteral excipient. Patentability would need to arise from a specific combination, concentration, stability result, container system, process, or use.

Is a premixed vasopressin product automatically therapeutically equivalent to concentrated vasopressin?

No. Therapeutic equivalence depends on the approved application, dosage form, strength, labeling, and FDA determinations. A premixed product may require a separate regulatory assessment.

Can a sponsor obtain new exclusivity by changing the vasopressin bag material?

Potentially, but a packaging change alone does not guarantee exclusivity. The change must support patentable technical features and satisfy FDA requirements for container compatibility, extractables, leachables, stability, and product performance.

What is the most valuable excipient innovation for vasopressin?

A stabilizing excipient is not necessarily the most valuable innovation. For this product, a formulation that delivers longer room-temperature stability with low impurity growth and low surface adsorption may have greater commercial value than a more complex excipient system.

Does hospital compounding eliminate the market for premixed vasopressin?

No. Compounding can compete on cost, but premixed products retain value through standardized concentration, reduced preparation labor, lower medication-error risk, simpler inventory management, and improved availability during high-demand periods.

References

1. U.S. Food and Drug Administration. (n.d.). Vasopressin injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2014). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.